News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Erasmus MC Study Shows Additional Role for Abiraterone in Blocking Tumor Growth in CRPC


3/15/2013 7:57:07 AM

As part of an EU-supported IMI-PREDECT consortium (http://www.predect.eu), a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC). The study, which won the first prize for best abstract in oncology at the 28th European Association of Urology (EAU) Congress to be held in Milan from March 15 to 19, demonstrated that although the use of abiraterone can potentially lead to an accumulation of precursor hormones, its anti-androgenic properties may stop precursor hormone-induced androgen receptor (AR) activation.

Read at EurekAlert!
Read at MedicalXpress

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES